Traders Buy Humana (HUM) on Weakness

Investors bought shares of Humana Inc (NYSE:HUM) on weakness during trading hours on Thursday. $75.01 million flowed into the stock on the tick-up and $52.87 million flowed out of the stock on the tick-down, for a money net flow of $22.14 million into the stock. Of all companies tracked, Humana had the 33rd highest net in-flow for the day. Humana traded down ($1.23) for the day and closed at $275.02

HUM has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $377.00 price objective for the company in a report on Thursday, October 4th. JPMorgan Chase & Co. raised shares of Humana from a “neutral” rating to an “overweight” rating and set a $283.00 price objective for the company in a report on Thursday, December 20th. Royal Bank of Canada raised their price objective on shares of Humana from $318.00 to $349.00 and gave the stock a “sector perform” rating in a report on Thursday, November 8th. SunTrust Banks raised their price objective on shares of Humana to $380.00 and gave the stock a “hold” rating in a report on Wednesday, September 19th. Finally, BMO Capital Markets set a $390.00 price objective on shares of Humana and gave the stock a “buy” rating in a report on Thursday, November 8th. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $349.53.

The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.68 and a current ratio of 1.68. The firm has a market cap of $37.90 billion, a price-to-earnings ratio of 24.21, a P/E/G ratio of 1.08 and a beta of 1.09.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, beating analysts’ consensus estimates of $4.29 by $0.29. The business had revenue of $14.21 billion during the quarter, compared to analyst estimates of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.10%. During the same quarter last year, the business posted $3.39 earnings per share. Equities research analysts anticipate that Humana Inc will post 14.43 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date of this dividend is Friday, December 28th. Humana’s dividend payout ratio is currently 8.54%.

In related news, insider Roy A. Beveridge sold 4,622 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total value of $1,576,379.32. Following the completion of the sale, the insider now owns 10,621 shares of the company’s stock, valued at $3,622,398.26. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David A. Jr/Ky Jones sold 600 shares of the firm’s stock in a transaction that occurred on Saturday, November 16th. The shares were sold at an average price of $88.05, for a total transaction of $52,830.00. The disclosure for this sale can be found here. In the last three months, insiders sold 9,078 shares of company stock valued at $2,570,350. 0.60% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of HUM. FMR LLC grew its holdings in Humana by 1.4% during the 3rd quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock worth $4,190,809,000 after acquiring an additional 167,283 shares during the period. BlackRock Inc. grew its holdings in Humana by 1.2% during the 3rd quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock worth $4,167,767,000 after acquiring an additional 140,731 shares during the period. Vanguard Group Inc grew its holdings in Humana by 1.4% during the 3rd quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock worth $3,420,482,000 after acquiring an additional 140,864 shares during the period. Capital International Investors boosted its position in shares of Humana by 3,030.3% during the third quarter. Capital International Investors now owns 8,217,296 shares of the insurance provider’s stock worth $2,781,719,000 after purchasing an additional 7,954,786 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Humana by 14.1% during the third quarter. Renaissance Technologies LLC now owns 3,174,800 shares of the insurance provider’s stock worth $1,074,733,000 after purchasing an additional 391,300 shares in the last quarter. 92.69% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Traders Buy Humana (HUM) on Weakness” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://sportsperspectives.com/2019/01/12/traders-buy-humana-hum-on-weakness.html.

About Humana (NYSE:HUM)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Featured Story: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply